The good and the bad of vitamin D inactivation 
Metabolites of vitamin D
Vitamin D deficiency is associated with impaired intestinal calcium absorption that leads to osteomalacia and rickets. The antirachitic properties of vitamin D were first established in the early part of the 20th century (1, 2) . Since then, many key steps in the synthesis, metabolism, and action of vitamin D have been elucidated, greatly improving the diagnosis and treatment of disorders of vitamin D action. Genetic studies have identified mutations in pathways required for activation of the vitamin D prohormone to the active 1,25-dihydroxyvitamin D hormone (Figure 1A) , which plays an important role in the absorption of calcium from the intestine, thereby promoting skeletal growth and mineralization.
While treatment with vitamin D or vitamin D-rich nutrients prevents the development of nutritional rickets, rickets associated with disorders of vitamin D activation is resistant to vitamin D therapy. Identification of the enzyme responsible for 25-hydroxylation of vitamin D in the liver remained elusive until a rare form of rickets was shown to result from inactivating mutations of CYP2R1 (3, 4) . The rare occurrence of this disorder and the relatively mild phenotype of affected individuals suggest compensatory effects of a second enzyme contributing to the 25-hydroxyvitamin D pool (5) .
Homozygous inactivating mutations of CYP27B1, the vitamin D 1-α hydroxylase, lead to pseudovitamin D deficiency rickets (6) . Affected individuals are unable to synthesize 1,25-dihydroxyvitamin D; thus, impaired intestinal calcium absorption leads to hypocalcemia, secondary hyperparathyroidism, rickets, and osteomalacia. This disorder is effectively treated with physiological doses of 1-α hydroxylated vitamin D metabolites. Although inactivating vitamin D receptor mutations also lead to impaired intestinal calcium absorption, affected individuals have very high concentrations of 1,25-dihydroxyvitamin D due to induction of CYP27B1 by the high levels of parathyroid hormone (PTH) and impaired catabolism of 1,25-dihydroxyvitamin D (7). Consistent with the high levels of circulating 1,25-dihydroxyvitamin D, individuals are resistant to treatment with vitamin D metabolites and may require parenteral calcium to circumvent the defect in intestinal calcium absorption.
Although the molecular basis for these disorders of impaired vitamin D activation and action has been appreciated for over two decades, abnormalities in pathways of vitamin D inactivation have only recently been identified (Figure 1B) . Homozygous mutations in the vitamin D 24-hydroxylase CYP24A1, the major enzyme responsible for inactivation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, lead to idiopathic infantile hypercalcemia (IIH). This disorder is characterized by increased serum concentrations of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, hypercalcemia, and hypercalciuria, which leads to nephrocalcinosis. This phenotype emphasizes the nonredundant effects of CYP24A1 in regulating the endocrine actions of active vitamin D metabolites (8, 9) .
Novel actions of 24R,25-dihydroxyvitamin D 3
While studies in avian models have implicated a role for 24R,25-dihydroxyvitamin D 3 
